Fast-Acting Relief Backed by Science for TRD

Living with depression can feel endless, especially when traditional medications take weeks or months to provide relief. For adults with treatment-resistant depression (TRD), this delay can be discouraging and isolating.[1]

Fortunately, Spravato® (esketamine) offers a new approach backed by science. Unlike most antidepressants that target serotonin, norepinephrine, or dopamine, Spravato works on the NMDA receptor, influencing glutamate, a neurotransmitter critical for mood and emotional regulation.[2] By targeting these pathways, Spravato may help “reset” the brain and relieve depressive symptoms faster than standard therapies.

How Quickly Can Spravato Work for TRD?

Clinical trials have shown that some patients notice improvements within days, compared to weeks required for oral antidepressants.[3] Rapid response can be life-changing, helping patients regain motivation, clarity, and the ability to participate in daily life and therapy sessions.

Safety and Monitoring

Spravato is administered under strict medical supervision in certified clinics, such as Adult Family Health Services. Each session includes:

• Self-administration of the nasal spray

• Two-hour observation for side effects like drowsiness or mild dizziness

• Required transportation home for safety

Treatment typically begins twice weekly and tapers as symptoms improve, combined with ongoing oral antidepressants and a comprehensive mental health plan.

The Science Behind the Relief

Research indicates that esketamine’s effect on NMDA receptors increases synaptic connectivity in the brain, which may contribute to its fast-acting antidepressant effects.[4] While not a cure, it offers an important tool for adults struggling with TRD, especially when other treatments haven’t worked.

Moving Forward

At Adult Family Health Services, we guide patients through every step of Spravato therapy, providing support and education to help maximize its benefits. If you’ve tried multiple antidepressants without success, Spravato may offer the fast-acting relief you’ve been seeking.

Contact Adult Family Health Services today to see if Spravato is right for you.

References

1. National Institute of Mental Health (NIMH). “Treatment-Resistant Depression.”

2. Janssen Pharmaceuticals. “Spravato® (esketamine) Nasal Spray Prescribing Information.”

3. U.S. Food & Drug Administration (FDA). “FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression.” 2019.

4. Duman RS, et al. “Synaptic Mechanisms of Rapid Antidepressant Action of Ketamine.” Biological Psychiatry. 2016; 79(4): 258–266.